SELLAS Life Sciences Gr Q1 2024 Adj EPS $(0.21) Misses $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group reported a Q1 2024 adjusted EPS loss of $(0.21), missing the consensus estimate of $(0.16) by 31.25%.

May 14, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SELLAS Life Sciences Group's Q1 2024 earnings report showed a larger loss per share than expected, missing the consensus estimate by 31.25%.
Earnings misses typically lead to negative investor sentiment in the short term, potentially causing a decrease in stock price. The miss by 31.25% is significant and likely to impact investor confidence negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100